Exploring Checkpoint Inhibition in Endometrial Cancers
Amanda Ramos, MD, a first-year fellow at the Massachusetts General Hospital in Boston, discusses the future potential of checkpoint inhibition therapy in the treatment of patients with recurrent endometrial cancers.
Watch
Optimizing Therapy at Progression of EGFR-Mutant NSCLC
EGFR-Mutant NSCLC: Selecting Patients for Osimertinib
Osimertinib's Value in EGFR-Mutant NSCLC
Systemic Therapy Options for Non-Small Cell Lung Cancer
EGFR-Mutant NSCLC: Optimizing Therapy Selection
Shifting Prognoses of Patients With EGFR-Mutant NSCLC
A Case of EGFR-Mutant Non-Small Cell Lung Cancer
Frontline Treatment Strategies in EGFR-Mutant NSCLC
Expert Highlights Testing Standards in Patients With Colorectal Cancer
Scott Kopetz, MD, associate professor of GI Medical Oncology at MD Anderson Center, advises community oncologists on what testing should be done for patients with colorectal cancer.
Mechanism of Action for TPO-RAs in ITP
ITP: Second-Line Therapy
Impact of Long-Term Immunosuppressive Therapy
Frontline Therapy for Immune Thrombocytopenia
Risks With Untreated ITP
Immune Thrombocytopenia Risk Stratification
Presenting With Immune Thrombocytopenia
Therapeutic Management of Immune Thrombocytopenia Case 2
Therapeutic Management of Immune Thrombocytopenia
Immune Thrombocytopenia: Impact of the EXTEND Trial
Duration of Platelet Recovery With TPO-RAs
Second-Line Therapy and Beyond for ITP
Effects of Long-Term Immunosuppressive Therapy
ITP: When to Switch to Second-Line Therapy
Immune Thrombocytopenia: First-Line Treatment Options
Diagnosing Immune Thrombocytopenia
A Case of Immune Thrombocytopenia
Therapeutic Management of Immune Thrombocytopenia Case 1
Potential of VRD + Daratumumab in Myeloma
Myeloma: Follow-Up and MRD Testing
Use of VMP + Daratumumab in Myeloma